What's New in Type 1 Diabetes: Immune Therapy and Screening Advances

Type 1 diabetes care is entering an exciting new phase. According to pediatric endocrinologist Dr. Brittany Bragman at the University of Florida, the past five years—and even the past year alone—have brought meaningful changes to how doctors treat and manage the condition. These advances are reshaping what's possible at the time of diagnosis and beyond.

One of the most significant recent developments is the FDA approval of teplizumab (Tzield) for use in people with newly diagnosed Type 1 diabetes. This immune therapy can be given right at the onset of symptomatic disease, offering patients a treatment option that was not previously available. Having an actual immune therapy to offer at diagnosis represents a meaningful shift in how doctors can intervene early in the disease process.

Another major area of development is screening for Type 1 diabetes. There is growing emphasis on identifying the condition earlier, though the full scope of screening approaches continues to evolve in clinical practice. This reflects a broader shift toward earlier detection and intervention.

For pediatricians and families alike, keeping up with Type 1 diabetes developments is more important than ever. The field is moving quickly, with new information and options emerging regularly. Understanding these advances helps ensure that patients receive the most current and effective care available.

Origin: YouTube / Contemporary Pediatrics (Video report). Evidence: Video report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.